Historically, the amyloidoses have been associated with inflammation and the immune response. From Virchow's original description in human pathologic inflammatory states through their identification in horses used to produce antitoxin to their frequent occurrence in the course of multiple myeloma and a somewhat abortive designation as 'gammaloid', the disorders were felt to have an inflammatory origin. These presumptive associations antedated the availability of a reliable method for tissue extraction that would allow chemical analysis of the major deposited molecules. With the identification of the multiple precursors and the realization that most were not intrinsic elements of immune/inflammatory pathways, the investigative emphasis shifted to the analysis of the biophysical events involved in aggregation and fibril formation. As more in vivo models and better tools for examination of tissues have become available, it appears as if inflammation may participate as both a response to, and an amplifier of, the effects of the fibrillar aggregates. Hence, while only a limited number of amyloid protein precursors are involved in immunity and inflammation per se, host defense, in its broadest sense, is likely to be involved in the clinically relevant amyloidoses. Further it now appears that harnessing the immune respone in an appropriate fashion may be able to play a role in treatment.
Introduction
Twenty-six different amyloid precursor proteins have been identified in various human amyloidoses and the disorders have now been classified according to the nature of the precursor, rather than the less precise clinical nomenclature utilized in the past (Table 1) .
A protein preamble
The relationship between in vitro amyloid formation and the amyloidoses:
In recent years, recombinant technology has allowed the bacterial synthesis and purification of a large number of proteins, including those known to form amyloid in vivo. This has been extremely useful in allowing the experimental dissection of the processes of aggregation and fibril formation that are intrinsic to the pathogenesis of these disorders. In addition, other disease-related proteins, including a-synuclein, the major component of Lewy bodies in Parkinson's disease and Huntingtin the aggregated poly-glu protein found in the cellular inclusions in Huntingtin's disease, when incubated under amyloid-forming conditions in the test tube, form fibrils with similar biophysical properties as the proteins involved in the human amyloidoses. 10, 11 In vivo these disorders do not have the histopathologic characteristics of the human amyloidoses and technically should not be referred to as such; however, it is possible that the same biophysical principles will prevail for these proteins as for those forming amyloid in vivo.
The proteins that have in vivo disease potential are inherently small (o30 kDa) or are cleavage products of larger molecules, suggesting that the amyloidogenic potential of a domain is reduced by its structural context, that is, embedded in a larger molecule, which requires either cleavage or denaturation to allow aggregation to begin. Some of the precursors seem to achieve the same protection by existing as a complex with other proteins, for example, immunoglobulin light chains with themselves as homodimers or in the H 2 L 2 tetramer or b 2 -microglobulin noncovalently complexed on the cell surface with major histocompatibility complex (MHC) class I heavy chains. Even more interesting are the observations that fragments or domains of some proteins, not shown to be associated with disease or in vivo deposition, when incubated under the appropriate conditions of concentration, ionic strength and pH will also behave in a fashion similar to those proteins responsible for the clinical amyloidoses. 12 Hence, the notion has arisen that the capacity to form the cross-bstructure characteristic of the amyloid protofibril is an intrinsic property of many proteins; hence, must have some structural features that have been selected through evolution as useful, particularly in the context of multidomain molecules. Several examples have now been described in which the amyloid structure serves an apparently normal physiologic function, notably the curli protein of escherichia coli, yeast prions and the melanosome melanin binding protein Pmel17. [13] [14] [15] Our discussions in this review will cover only those conditions in which tissue deposits fulfilling the pathologic criteria for amyloid, that is, Congophilia, ultrastructurally fibrillar, co-deposited SAP, ApoE and Perlecan, are found. For the most part the deposits are extracellular, although there are now instances in which it has been reported that the earliest steps in aggregation can be seen intracellularly.
For most of the history of amyloid research, the manifestations of the disease were felt to be the result of tissue replacement or displacement by the masses of amyloid fibrils deposited in tissue parenchyma. Recent studies with some precursors in tissue culture systems have suggested that small oligomeric aggregates that are preprotofibrillar may be toxic to cells. [16] [17] [18] Definitive evidence that this occurs in vivo has not yet been presented, although there are experiments suggesting that this might be the case. 19 
Mechanisms of amyloidogenesis in humans
There are several general processes that lead to clinical amyloidosis ( Figure 1 ). In one group of precursors, overproduction or failure to excrete an intact molecule that has a concentration dependent tendency to misfold, for example, ANF, b 2 microglobulin and IAPP, is sufficient. [20] [21] [22] These molecules require no other processing to form fibrils, although partial proteolysis might enhance their fibril forming capacity. In a second class, the intact molecule is not amyloidogenic but abnormal site specific proteolysis generates an amyloidogenic fragment, e.g Alzheimers Disease (Ab). 23 In a third pathway, inadequate normal proteolytic cleavage yields an amyloidogenic fragment. This may occur when the substrate is overproduced and there is a relative insufficiency of the normal degradative pathway with respect to the increased precursor load, as may be the case in AA and perhaps in associated amyloidesis (AL), A(tbn), to be named. The designation is waiting for a protein name.
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In the case of the homotetrameric protein transthyretin (TTR), a shift in the equilibrium between tetramer and monomer leads to the enhanced population of a monomer pool predisposed to misfold. The equilibrium is shifted toward the misfolded monomer by the presence of any of 80 þ of mutations. 26 It is also likely that proteolysis will accelerate the process. In the case of the prionoses, the native proteins appear to require no particular primary sequence change or cleavage and may not be overproduced. It seems that they only require the presence of an amyloidogenic folding template, that is, the prion seed. 27 Amyloidosis as a consequence of a primary genetic disorder
The hereditary aspects of this subset of amyloidoses reside in conditions that increase the production of a protein that at normal concentrations does not form significant amounts of amyloid. In the genetic disorder multiple endocrine neoplasia (MEN) type 2A individuals, who have mutations in the RET proto-oncogene represent 20% of cases of medullary carcinoma of the thyroid (MCT) in which the overproduction of procalcitonin leads to local amyloid formation. 28 Histologically demonstrable procalcitonin-derived amyloid is a major feature in 30-40% of MCT, the majority of which are not associated with MEN 2A. 29 Hence, the genetic lesion predisposes to the tumor, not its tendency to form a particular species of amyloid. One-third of MEN 2A patients, apparently all with a mutation at position 634 in RET, have cutaneous lichen amyloidosis, Congophilic deposits in which the fibrils appear to be derived from cytokeratin. 30, 31 It has not been established that the cytokeratins are of wild-type sequence. Further the process of fibril formation has not been examined experimentally. It is not clear why some of these patients have localized procalcitonin or cutaneous amyloid and others do not. The distinction may totally reside in the amount of precursor that is available. Alternatively it may result from the action of alleles at loci that impact on the process of amyloidogenesis or influence the removal of protein aggregates from local areas. In formal genetic terms, this would be assessed by determining interaction effects between the major gene responsible for the primary disease and potential candidate genes hypothesized to be involved or family studies in which the property segregated in a defined fashion.
Additional instances in which a primary genetic disorder leads to amyloidosis are found in the hereditary disorders of the innate inflammatory pathway, including Familial Mediterranean Fever (FMF), etc (see below). These are inherited in either an autosomal recessive or dominant fashion and result in recurrent episodes of systemic inflammation and increased production of SAA, the Amyloid A (AA) precursor. 32 Individuals, bearing particular alleles of SAA genes, are at increased risk for hepatic and renal amyloidosis (see below and Table 5 ). In these cases, the amyloid precursor has the wild-type structure, the mutation being in the molecule responsible for the exuberant inflammatory response.
The other class of amyloidoses that has a major genetic component includes autosomal dominant disorders in which a structural abnormality in a potential amyloid substrate, usually a mutation, generates a protein with a pathologic gain of function, that is, the property of becoming insoluble under physiologic conditions. These include the disorders related to mutations in transthyretin, In transthyretin FAP, the fibril precursor is a misfolded monomer formed after native monomer is released from the tetramer. In Alzheimer's disease the fibril precursor, Ab, is released by a series of cleavages from the precursor AbPP (Ab protein precursor). In reactive (AA) amyloidosis, the production of the SAA precursor exceeds the capacity of the normal degradative mechanisms to completely digest the core AA molecule. This is also likely to be true in AL. In the prion diseases, no processing of the native protein appears to be necessary in the face of adequate amounts of misfolded template.
fibrinogen, gelsolin, the Abeta precursor protein (APP), apolipoprotein A1, lysozyme and cystatin. [33] [34] [35] [36] [37] [38] [39] Considerable progress has been made in understanding the process of in vitro fibrillogenesis in almost all of these cases; however, the same precision has not been achieved in studying the processes in vivo.
Mutations in genes that encode molecules that process a potentially amyloidogenic substrate into a nonamyloidogenic peptide can also result in clinical amyloidosis. The most common mutations in early onset, autosomal dominant Alzheimers Disease are in the presenilin genes PS-1 and PS-2, which are components of the a-secretase complex, and result in alterations in the cleavage patterns of AbPP with increased concentrations of the amyloidogenic Ab 1À40 and Ab 1À42 precursors. [40] [41] [42] It is possible that polymorphisms in genes that process transthyretin, anf, iapp, apoA1, prolactin and others that process or chaperone Ab may contribute to the deposition of these wild-type molecules late in life, although at this time there is little genetic evidence to suggest that this is the case.
Amyloidoses derived from molecules involved in immune function
The immunoglobulin associated amyloidoses The amyloidoses that are most intimately related to the immune system are those derived from immunoglobulin (Ig) chains. AL, the amyloid consisting of immunoglobulin light chains or their fragments and the far less commonly seen AH, in which the amyloidgenic heavy chain fragment results from a domain length deletion in the Heavy chain gene, are both secreted products of monoclonally expanded B cell populations. The L-chains may be intact or truncated while the H-chain related proteins usually have internal deletions. 43 The proliferative disorder may have the clinical neoplastic characteristics of multiple myeloma or those of a monoclonal gammopathy of undetermined significance (MGUS). 44 In either case, the protein product is pathogenic producing renal, cardiac or neuropathic clinical symptoms when it deposits in those organs. The somatic cell genetics of these disorders have been extensively studied from the point of view of oncogenesis as have the structural features of kappa and lambda light chains, which appear to favor amyloid formation and will not be discussed here. [45] [46] [47] There are several reports of the familial incidence of myeloma, the germline genetics of which have not been established. 48 There are a smaller number of reported instances of familial AL but no genetic studies have been performed on any of these very rare kindreds 49, 50 Interestingly, a number of studies have reported that African-Americans have a higher frequency of multiple myeloma and examination of the Department of Veterans Affairs inpatient data base suggests that they also have a higher frequency of AL. 51 Similarly, an extensive autopsy series indicated that Hispanics of Mexican descent seemed to have a higher prevalence of both AL and AA, but neither observation has been confirmed by a formal epidemiologic study nor have they been subjected to genetic analysis; hence, the possibility remains that the effect may be environmental rather than genetic. 52 b 2 -Microglobulin (dialysis-AL) Amyloid deposition consisting of b 2 -microglobulin, the light chain of class I MHC molecules expressed on the cell surface is very common among patients with chronic renal failure, who are maintained on chronic hemodialysis, being virtually universal after 15 years of such treatment. 53 There does not appear to be any genetic component determining either the frequency or time of appearance of the deposits, which is a function of both the nature of the dialysis membrane and characteristics of the dialyzing fluid. 54, 55 Attention to both has resulted in a gradual decline of this iatrogenic form of amyloidosis.
Amyloid A The third form of systemic amyloidosis of intrinsic interest to immunologists is that produced by the deposition of AA fibrils. 56 AA is a cleavage product of the normal serum protein SAA, which circulates in a complex with high-density lipoproteins and is highly elevated in the course of acute and chronic infectious or noninfectious inflammatory responses. 57, 58 The protein appears to play a role in lipid handling by macrophages, and there has been some speculation that this process may be actively involved in atherogenesis. 59 The hepatic transcription of the gene is highly sensitive to interteukin (IL)-6, which in turn may be influenced by IL-1 and tumor necrosis factor alpha (TNFa). The gene is also actively transcribed in cells other than hepatocytes. 60 Historically, prior to the availability of relatively effective anti-inflammatory therapy, as many as 25% of patients with long-standing rheumatoid arthritis (RA), a classic autoimmune process, developed renal, hepatic and splenic amyloidosis, with renal failure a common cause of death. 61 With more aggressive modes of therapy the incidence is now approximately 5% in the US with only half of those with positive screening biopsies (abdominal fat or rectal) having clinically significant deposition. 62 A prolonged inflammatory state is required for AA deposition but it is not sufficient. The amount of SAA precursor available plays some role since it has been shown that keeping the serum SAA level below 10 mg/l prevents clinical progression; however, it is unclear that the risk for amyloid deposition increases once one goes above that level. 63 It appears that the propensity toward amyloid deposition in the presence of systemic inflammation is determined by its severity and chronicity, and conditioned by specific alleles encoding the various isoforms of SAA. The relevant susceptibility alleles vary in different populations ( Table 3) .
The three SAA isoforms (SAA1, 2 and 4) are encoded by three homologous genes (Table 2) . 64, 65 All are located on human chromosome 11 (and mouse chromosome 7). 66 One, SAA4, encodes a molecule which is 52% homologous at the amino-acid level and has not been found to be an amyloid component. There is also a pseudogene which is not expressed. The SAA1 gene has five alleles (Table 2) . SAA2 has two. Both SAA1 and 2 proteins have been identified as amyloid components in humans while SAA2 is the major fibril component in mice.
Over the last 10 years, it has become clear that the distribution of SAA alleles in individuals who develop amyloid in the course of inflammatory diseases differs from appropriate population controls. Further it appears that particular alleles may impart increased susceptibility in some populations but not in others, and in at least one instance interactions of alleles at different snp's in the same gene appear to increase the risk.
In Asian (Japanese, Korean, Taiwanese) control populations, the SAA 1 allele frequencies are quite similar (Table 3) . 67 The three alleles (1.1, 1.3 and 1.5) being relatively equally represented with some skewing toward SAA 1.3. In Caucasian groups, SAA 1.1 is much more common being significantly higher than in the Japanese controls. 68, 69 In Japanese RA patients without a tissue diagnosis of amyloidosis, the allele distributions do not differ from controls without RA (Table 3) . 70 However, in several studies of Japanese patients with RA and amyloid SAA 1.3 was significantly overrepresented, particularly in the homozygous state. 71, 72 One analysis, rather than showing a significant increase in SAA 1.3, showed only a decrease in the 1.1 allele in the amyloid patients (P ¼ 0.002). 69 In that same study, the increase in SAA 1.3 was not quite significant (P ¼ 0.06), suggesting perhaps that the study did not have sufficient power. The difference between the RA patients with amyloidosis and the population controls without RA was statistically more impressive (P ¼ 0.01). In US patients with RA the frequency of SAA 1.1 is significantly higher in patients with amyloid than in nonrheumatoids without amyloid, not unexpectedly resembling the UK distribution more than that in Japan. 69 Recent findings have suggested that another polymorphism in the SAA 1 gene, at position À13 in the 5 0 regulatory region of the gene is more closely associated with the occurrence of amyloid in both Japanese and Caucasian RA patients than any of the prior exon 3 based allelic associations. 69 The frequency of the TT allele is higher in Japanese than in the Caucasians. The association of the TT and SAA 1.3 alleles is not significantly greater in the amyloid patients (P ¼ 0.09), but a larger sample size might demonstrate a synergistic effect of the two snp's. A recent functional study suggests that the TT allele has greater transcriptional activity, a finding that would predict an interaction between them. 73 Two studies of Japanese RA patients with and without amyloidosis did not show differences in the distribution allele frequencies at the SAA 2 locus. 67, 74 However, an analysis of juvenile chronic arthritis (JCA) patients in the UK showed that the a-allele was more common in those with amyloid than in those without amyloidosis, but that allele was also more common in both JCA groups than in the controls (P ¼ 0.04), suggesting perhaps that the allele may play a role in the pathogenesis of JCA. 75 Among patients with JCA in Great Britain, SAA 1.1 is significantly increased in those with amyloidosis over both JCA patients without amyloid and controls; however, the difference in the frequency of SAA 1.1 between adult RA patients from the A57V  D60N  F69L  G70T  N84K  G90R  SAA2.2  V52A  A57V  D60N  F69L  H72R  N84K  G90R Amino-acid sequences are identical except for positions noted: A, alanine; D, aspartic acid; F, phenylalanine; G, glycine; H, histidine; K, lysine; L, leucine; N, asparagines; R, arginine; T, threonine; V, valine. (8) 14 (28) 9 (18) 4 (8) 10 (20) (12) 10 (20) 10 (20) 3 (6) 12 (24) The genetics of the amyloidoses J Buxbaum same center with and without amyloid as a complication was not significant (P ¼ 0.07) ( Table 4) . 68 Similar analyses have been performed in populations defined by the mutations in genes that are responsible for the hereditary inflammatory diseases FMF, Familial Cold Urticaria (FCAS), Muckle-Wells Syndrome (MWS), Hyperimmunoglobulinemia D with periodic fever syndrome (HIDS), TNF-receptor associated periodic syndromes (TRAPS), Neonatal-onset inflammatory disease/ chronic infantile neurologic cutaneous and articular syndrome (NOMID/CINCA) and Pyogenic arthritis with pyoderma gangrenosum and acne (PAPA). [76] [77] [78] [79] All of these are characterized by recurrent febrile episodes with various constellations of clinical features. AA amyloidosis is common in FMF, rare in HIDS, uncommon in FCAS, present in about 10% of cases of TRAPS, and 25% of MWS. No cases have yet been reported in PAPA and only a few in NOMID/CINCA cases who reach adulthood. As in sporadic AA deposition is largely renal, hepatic and splenic. We will not discuss the genetics of these disorders since several recent reviews have covered the subject in great detail. All have mutations in genes involved in apoptotic events in cytokine mediated inflammatory pathways except for HIDS where the mutations are in mevalonate kinase gene. The relationship of this gene to intrinsic inflammatory processes is unclear. 77, 78, [80] [81] [82] [83] The prototypic and most frequently described of these disorders, FMF is autosomal recessive as is HIDS. The others appear to have dominant inheritance. The relatively large number of individuals with FMF that have been studied in detail, and the fact that the disorder has occurred on a variety of ethnic backgrounds has allowed some insight into the pathogenesis of the disease. On clinical grounds, it was predicted more than 10 years ago that another gene in addition to that responsible for the FMF syndrome would be responsible for the occurrence of amyloidosis in this disorder. 84 The comparison of the SAA allele distributions in these disorders with those in RA is interesting because the two sets of disorders have arisen in populations with genetic histories that are likely to be quite different. Studies of FMF kindreds indicate that one must be homozygous for an FMF pyrin gene mutation (most commonly M694V) to display the febrile phenotype. However, the appropriate allele of the SAA1 precursor isoform increases the risk of developing amyloid deposition in the course of the periodic inflammation, particularly if one is homozygous (Table 5 ). It appears that, in the presence of the same pyrin mutation (M694V), homozygous SAA1.1 Israeli, Armenian and Turkish FMF patients are at greater risk for amyloidosis. 85, 86 These observations reinforced, but did not fully conform to, findings in RA patients (see above). In both the Israelis and Armenians, male sex as well as the SAA1.1 allele are associated with a higher frequency of renal amyloidosis. 87, 88 A similar analysis in patients with the HIDS, who rarely have amyloid, did not show any difference in the distribution of SAA alleles compared to population controls despite the fact that they had very high SAA levels. No studies were carried out to determine the distribution of the À13 T/C alleles in the SAA promoter. 89 The data suggest that prolonged SAA elevations alone may not be sufficient to uniformly result in AA deposition, leaving the way open for the action of other gene products to play a role.
Interfaces between the amyloidoses and the immune system
The pathologic examination of amyloid infiltrated tissues has generally failed to reveal any of the conventional (27) 42 (42) 3 (3) 22 (22) 5 (5) The genetics of the amyloidoses J Buxbaum hallmarks of inflammation. In some experimental models of AA, however, there appears to be considerable mononuclear activation. Some have interpreted this as reflecting an attempt to clear the deposits. 90 The alternative explanation is that the macrophages contribute to deposition by cleaving the precursor SAA, to release AA capable of forming fibrils in situ. Mixed cultures of SAA-producing hepatoma cells or hepatocytes and macrophages have been reported to produce AA fibrils in tissue culture. 25 A single published mixed culture experiment with human bone marrow cells and macrophages from an amyloid patient suggested a similar process. 91 More recent studies in which L-chains isolated from patients with AL and light chain deposition disease were incubated with cultured human mesangial cells seem to demonstrate cleavage of the amyloidogenic L-chains with subsequent fibril formation, a very interesting result awaiting confirmation in other laboratories. 92 In vivo models in which L-chain fibrils are injected subcutaneously in mice have shown resorption of the aggregates with the major cellular player appearing to be neutrophil. The process then can be accelerated by passive administration of an apparently conformation specific antibody. 93, 94 In contrast to the systemic amyloidoses, it has been well recognized that glial activation is common, if not universal, in the neighborhood of Ab plaques in the Alzheimers Disease brain. 95 It has been experimentally shown that Ab fibrils can activate glia and this may be mediated by the nuclear factor kappa B pathway triggered via RAGE or CD36. [96] [97] [98] Glial activation seems to result in more Ab production as well, again suggesting that an apparent defense mechanism may actually enhance the pathologic process. It remains an open question whether these responses are intrinsic to the basic process of fibril formation or whether they represent host defenses to the abnormal conformers, which are inadequate to eliminate the insult but by responding actually increase the damage.
The other side of the inflammatory coin with respect to the amyloidoses is represented by the relatively successful attempts to immunize both experimental animals and humans to the fibril precursor. The initial attempts to immunize mice transgenic for human mutant APP genes with the amyloidogenic fragment were startlingly successful, with impressive plaque resolution. 99 The results were significant enough to result in a clinical trial. Unfortunately, perhaps predictably, about 5% of the immunized individuals developed severe inflammatory disease of the central nervous system. 100, 101 The frequency of the severe adverse reaction was actually less than one might expect, considering that while the AD mice were being immunized with a human protein (less likely to be homologous to an endogenous functional murine molecule), the trial involved immunizing humans with a human protein and some autoreactivity was likely. Nonetheless pathologic examination of the brains of some of the individuals suggested reductions in plaques. 102 Subsequent studies have shown that passive immunization with antibodies directed toward particular Ab epitopes could be carried out in the transgenic mice, and trials with humanized antibodies of relatively refined specificities are now ongoing. 103, 104 The success of this approach has led to similar animal studies in models of AL and the transthyretin amyloidoses with some success. 94, 105 These will presumably lead to human trials with appropriately humanized monoclonals that have been effective in the murine models.
Other genetic lessons learned from the amyloidoses
The interaction of specific alleles at the SAA loci with the genes encoding the hereditary periodic inflammatory disorders to predispose to amyloid formation is an instructive example of the emerging concept that there are no single gene diseases. Another, perhaps more subtle, instance is seen in patients with Familial Amyloidotic Polyneuropathy (FAP) related to mutations in transthyretin. The homotetramer is composed of four 127 amino-acid monomers. Over 100 mutations have been reported at 50 positions in the peptide. Ninety of these appear to be associated with tissue amyloid deposition. (http://www.bumc.bu.edu/Dept/Content. aspx?departmentid ¼ 354&PageID ¼ 5530).
While many of the mutations have only been reported in a single or small number of kindreds, it has been suggested that particular mutants may be associated with characteristic clinical presentations, 106 in a fashion similar to the case in cystic fibrosis where the severity of the disease varies with the particular mutation. Among the TTR mutants only a few have been seen in enough individuals to derive a statistically valid impression regarding the association between the mutation and clinical presentation. FAP, in which the valine at position 30 is replaced by methionine (TTR V30M), has been reported in approximately 1500 individuals in 500 kindreds in Portugal, as well as in Japan and in Sweden. 107, 108 In Sweden, the allele shows low clinical penetrance and late onset. While the disorder was known to behave as an autosomal dominant, almost from the time of its original description, with increasing numbers of carriers analyzed it has become clear that the phenotype varies with respect to age of onset, the presence of cardiac and renal involvement in both Portugal and Japan. A recent analysis of Portuguese gene carriers has suggested that the age of onset is influenced by interactions among genes known to be involved in either the process of deposition or the carrier function of the TTR molecule, that is, ApoE, SAA1, SAA2, APCS, RBP4. Single-nucleotide polymorphisms in these genes were examined for their association with early or late onset. Those studies did not show significant effects of any of the five genes analyzed, but demonstrated that many more interactions among alleles at these loci occurred in patients with late onset of the disease than among individuals with early onset. 109 These results suggested that early onset was the default state of the mutation and interactions with the products of some of these alleles delayed the appearance of symptoms, contributing perhaps 25% to the late onset phenotype. The sample size was not sufficiently large to establish whether single gene effects were also present. However, it is worth noting that apart from the alleles at SAA1 and SAA2, which we have described above, prior studies have shown no association of amyloid deposition with alleles at APCS or RBP4. There is a well described association of ApoE4 with sporadic Alzheimer's Disease. 4, [110] [111] [112] However, studies with other amyloidoses including AA, AL and TTR V30M FAP have not shown any such association.
These types of gene interactions could be responsible for variation in the phenotype of disorders that in fact are not related to single major gene effects, for example, any of the autoimmune disorders such as SLE or RA, where it is already known that multiple alleles of multiple genes contribute to the clinical course.
Conclusions
The availability of methods to analyze tissue deposits has allowed the identification of more than two dozen precursor proteins as being responsible for the human and animal tissue pathology we define as amyloidosis. While the original, and still the quantitatively major associated disorders, that is, infectious and noninfectious inflammation and monoclonal B-cell disorders, have their genesis in the immune/inflammatory system, endocrine, neoplastic, and hereditary conditions are also etiologically responsible. However, it appears that there may be local inflammatory components involved in both the pathogenesis of, and the response to, the deposits. These may also be under genetic control and contribute to the clinical phenotype. The total number and nature of these genes remains a subject of speculation and active investigation.
